Bruce Robinson — ASN Events

Bruce Robinson — ASN Events

, ,

Presentations this author is a contributor to:

Efficacy and safety of lenvatinib for the treatment of patients with ¹³¹I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy (#362)

Effect of age and lenvatinib treatment on overall survival for patients with ¹³¹I-refractory differentiated thyroid cancer in SELECT (#363)